bcr-kit — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T4320	Flumatinib	HHGV678	Bcr-Abl , PDGFR , c-Kit
	Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.		Bcr-Abl , PDGFR , c-Kit
T4191	Multi-kinase inhibitor 1	Multi-kinase inhibitor I	Others , Bcr-Abl , PDGFR , c-Kit
	Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.		Others , Bcr-Abl , PDGFR , c-Kit
T6230	Imatinib	STI571,CGP057148B,ST-1571	SARS-CoV , Bcr-Abl , PDGFR , c-Kit , Autophagy
	Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the tre...		SARS-CoV , Bcr-Abl , PDGFR , c-Kit , Autophagy
T4053	AST 487	NVP-AST 487	VEGFR , FLT , c-RET , Bcr-Abl , c-Kit
	AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.		VEGFR , FLT , c-RET , Bcr-Abl , c-Kit
T1621	Imatinib Mesylate	ST-1571 Mesylate,STI-571,CGP-57148B	Bcr-Abl , PDGFR , c-Kit , Autophagy
	Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).		Bcr-Abl , PDGFR , c-Kit , Autophagy
T7861	Flumatinib mesylate	HHGV678 mesylate	Bcr-Abl , PDGFR , c-Kit
	Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.		Bcr-Abl , PDGFR , c-Kit
T1925	PLX647		c-Fms , c-Kit
	PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).		c-Fms , c-Kit
T23128	PD180970	PD 180970	Bcr-Abl , Src , c-Kit
	PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit. PD180970 can be used in studies about chronic myelogenous leukemia.		Bcr-Abl , Src , c-Kit
T6311	Bafetinib	NS-187,INNO-406	Bcr-Abl , Src , Autophagy
	Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.		Bcr-Abl , Src , Autophagy
T2640	Rebastinib	DCC2036,DCC 2036,DCC-2036	Apoptosis , FLT , Bcr-Abl , Src
	DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Re...		Apoptosis , FLT , Bcr-Abl , Src
T6079	NVP-ADW742	ADW742,ADW,GSK 552602A	Apoptosis , IGF-1R
	NVP-ADW742 (ADW) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.		Apoptosis , IGF-1R
T68607	AP23848
	AP23848 is a potent Bcr-Abl inhibitor. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth.
T11640	Imatinib-d8	CGP-57148B D8,STI571 D8	Others
	Imatinib D8 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.		Others
T11639	Imatinib D4	CGP-57148B D4,STI571 D4	Others
	Imatinib D4 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.		Others
T38653	HG-7-85-01
	HG-7-85-01 is a type II ATP competitive inhibitor targeting wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. It effectively inhibits T315I mutant Bcr-Abl kinase, as well as KDR and RET k...
T73973	Imatinib Impurity E
	Imatinib Impurity E is a specific impurity found in Imatinib, an orally available inhibitor of multiple tyrosine kinases, including BCR/ABL, v-Abl, PDGFR, and c-kit. Imatinib (STI571) operates by semi-competitively inhib...